Related Experiment Video
Updated: Aug 16, 2025

Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
Inhibition of NADPH Oxidases Prevents the Development of Osteoarthritis
Jin Han1, Donghwi Park1,2, Ji Young Park3
1Laboratory for Arthritis and Cartilage Biology, Research Institute of Aging and Metabolism, Kyungpook National University, Daegu 41404, Republic of Korea.
Abstract:
Increased oxidative stress in osteoarthritis (OA) cartilage mediates catabolic signal transduction leading to extracellular matrix degradation and chondrocyte apoptosis. This study aimed to explore the contribution of NADPH oxidase (NOX), a major source of cellular reactive oxygen species (ROS), to the catabolic process of chondrocytes and to OA. The inhibition of NOX isoforms with a pan-NOX inhibitor, APX-115, significantly decreased IL-1β-induced ROS production in primary chondrocytes and, most potently, suppressed the expression of oxidative stress marker genes and catabolic proteases compared with the inhibition of other ROS sources. Catabolic stimuli by IL-1β treatment and in post-traumatic OA conditions upregulated the expression of NOX2 and NOX4 in chondrocytes. In the post-traumatic OA model, the pharmacologic inhibition of NOX protected mice against OA by modulating the oxidative stress and the expression of MMP-13 and Adamts5 in chondrocytes. Mechanistically, NOX inhibition suppresses Rac1, p38, and JNK MAPK signaling consistently and restores oxidative phosphorylation in IL-1β-treated chondrocytes. In conclusion, NOX inhibition prevented the development of OA by attenuating the catabolic signaling and restoring the mitochondrial metabolism and can thus be a promising class of drug for OA.
Insights
NADPH oxidase (NOX) inhibition reduced oxidative stress and cartilage degradation in osteoarthritis (OA). This approach protected against OA development by targeting key catabolic pathways and restoring mitochondrial function.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoarthritis (OA) involves oxidative stress, leading to cartilage breakdown and chondrocyte death.
- NADPH oxidase (NOX) is a primary source of reactive oxygen species (ROS) implicated in OA pathogenesis.
Purpose of the Study:
- To investigate the role of NOX in chondrocyte catabolism and OA.
- To evaluate the therapeutic potential of NOX inhibition in OA.
Main Methods:
- Utilized a pan-NOX inhibitor (APX-115) on primary chondrocytes and a post-traumatic OA mouse model.
- Assessed ROS production, oxidative stress markers, catabolic gene expression (MMP-13, Adamts5), and signaling pathways (MAPK).
Main Results:
- APX-115 significantly reduced IL-1β-induced ROS and suppressed oxidative stress markers and catabolic proteases.
- NOX inhibition protected against OA in vivo by modulating oxidative stress and key catabolic enzymes.
- NOX inhibition attenuated Rac1, p38, and JNK MAPK signaling and restored mitochondrial function.
Conclusions:
- NOX plays a critical role in OA pathogenesis by driving oxidative stress and catabolic signaling in chondrocytes.
- NOX inhibition represents a promising therapeutic strategy for OA by mitigating cartilage degradation and restoring cellular metabolism.
Related Concept Videos
Oxidation of Phenols to Quinones
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox...
Radical Autoxidation
Feedback Inhibition
Osteoclasts in Bone Remodeling

